Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) has earned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. […]
MENLO PARK, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor...
Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) – Equities researchers at Truist Financial upped their Q1 2022 earnings per share (EPS) estimates for shares of Adicet Bio in a research note issued to investors on Thursday, March 31st. Truist Financial analyst A. Goonewardene now forecasts that the company will post earnings of $0.08 per share […]
MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on March 31, 2022 (the “Grant Date”) under Adicet’s 2022 Inducement Plan as a material...
Sumitomo Mitsui Financial Group started coverage on shares of Adicet Bio (NASDAQ:ACET – Get Rating) in a report issued on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $28.00 price target on the stock. A number of other research firms have also recently commented on ACET. StockNews.com assumed coverage on Adicet Bio […]